Sage Spurns Biogen, Turns Attention To Strategic Review

Proposed Deal’s Value Seen As Too Low

 
• By Mandy Jackson
  
Sage is reviewing strategic alternatives rather than accepting Biogen's buyout bid (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Scrip